DEFINITIONS:

1. Centers for Medicare and Medicaid Services (CMS) Diagnosis Codes and Modifiers identify qualifying clinical trials and differentiate between routine/standard and investigational clinical services.

2. Conduct of Clinical Research includes intervening or interacting with participants, obtaining informed consent, obtaining identifiable private information or biological specimens, administering investigational procedures or products, and receiving an award through a grant/contract.

3. Coverage Analysis (CA) is a detailed review of research items, services, procedures and Medicare billing rules to determine the appropriate payer/funding source for each.

4. Qualifying Clinical Trials (QCTs) are research projects that meet the Medicare Clinical Trial Policy criteria to receive Medicare coverage for routine/standard care items and services.

5. Third-Party Payers are institutions or companies that provide reimbursement to health care providers for services rendered to a third party (i.e., the patient).

PURPOSE:

To ensure appropriate billing of research-related charges by OSF HealthCare System ("OSF") business units.

POLICY:

1. This policy applies to all OSF business units involved in clinical research billing and administration, including Clinical Research Administration, the Common Business Office (CBO), the Patient Accounting and Access Center (PAAC), as well as individual principal investigators (PIs) conducting clinical research involving billable services at OSF.

2. OSF bills clinical services rendered during the course of a clinical research study to the appropriate sponsor, study account, third-party payer, or individual in compliance with applicable state and federal regulations.

3. Research participants and payers are not billed for:
   a. Services the sponsor is already paying for
   b. Services promised for free
   c. Services that are for research purposes only
The investigational item or services unless otherwise covered outside of the clinical trial

4. CMS Publication 100-04, Chapter 32, Section 68 and 69, is followed when billing Medicare for routine care services and/or medical devices provided in a clinical research study.

5. When a research study conducted at OSF includes billable services, no subject is enrolled until a CA is completed by Research Administration in consultation with appropriate business units and the PI.

6. The CA includes a QCT analysis in accordance with the criteria in CMS National Coverage Determination (NCD) 310.1, the Medicare Clinical Trial Policy or the Medicare Benefit Policy Manual Chapter 14, Medical Devices.

7. The CA includes an analysis of items and services identified in the study to determine which are considered routine or “standard of care.”

8. The CA is updated when there are changes to procedures or terms during the course of a study.

9. New and updated CAs are reviewed and signed by the PI.

10. At the discretion of Research Administration, CAs signed by non-OSF PIs are submitted prior to receiving facility permission to conduct the clinical trial.

11. At the request of a non-OSF PI, Research Administration provides CA services for an agreed upon fee.

**PROCESS:**

**Billing**

1. PIs, departments, administrative units, and OSF entities coordinate activities to ensure services associated with research studies are billed appropriately and in compliance with relevant laws, regulations, contractual obligations, and the policy for Claim Development and Submission Process (CC-115).

2. The PI or delegate is responsible for proper patient registration and notifies Research Administration upon research participants being enrolled and/or completing research related encounters.

3. Clinical Research Administration, the CBO or the PAAC appends the appropriate codes, modifiers, National Clinical Trials number (NCT #), and other identifiers to claims when billing Medicare for routine care services and/or medical devices provided in a clinical research study, including:
   a. Diagnosis Code V70.7 (ICD 9) or Z00.6 (ICD 10)
   b. Condition Code 30
   c. Condition Code 53
   d. Q0 for lines that contain an investigational item
   e. Q1 for lines that contain a routine service
   f. NCT #
   g. Investigational Device Exemption number (IDE #) for device studies, if applicable
   h. Premarket Approval number (PMA #) for device studies, if applicable
   i. Humanitarian Device Exemption number (HDE #) for device studies, if applicable

**Coverage Analysis**

1. Obtain the documents needed to conduct the CA, which include but are not limited to:
a. research study protocol, including the schedule of events  
b. informed consent document, including attachments and amendments  
c. clinical trial agreement (CTA) or notice of grant award, including attachments and amendments  
d. FDA status of the investigational item (IND, IND exemption, IDE)  
e. sponsor proposed budget

2. Conduct a QCT analysis according to the criteria in CMS National Coverage Determination (NCD) 310.1, the Medicare Clinical Trial Policy or the Medicare Benefit Policy Manual Chapter 14, Medical Devices.

3. Incorporate Local Coverage Determinations (LCDs) into the CA in the absence of a CMS NCD.

4. Conduct an items and services analysis, including a grid that outlines services required by the protocol and designates whether each service is research related or routine/standard of care.
   a. Review objective research documents and nationally recognized treatment guidelines, peer reviewed literature, and hospital treatment guidelines to identify which items are experimental (for research purposes only) and which are considered treatment for the condition being studied.
   b. Consult the PI or medical department head when there is incomplete information or no national standard available.
   c. Remove services designated as research related from participant third-party payer invoices.
   d. Include services designated as routine/standard of care on participant third-party payer invoices.

5. Obtain the review and approval signature of the PI to validate the CA.

6. Review and approve the CA.

7. Create a one-page analysis document to outline reasoning when it is determined that a full CA is not needed for a research project.

8. The PI or delegate notifies Research Administration of amendments or sponsor changes to the research in order to update the CA.

**Monitoring and Enforcement**

1. Research Administration conducts periodic quality assurance monitoring to evaluate compliance with this policy and related procedures.

2. This policy is consistently enforced through appropriate corrective and/or disciplinary measures when violations are identified.

3. Corrective measures for violation of this policy include, but are not limited to:
   a. suspension of study activities
   b. suspension of billing to participants and third-party payers
   c. reassignment of claims from billing entities to research accounts

4. Disciplinary measures are determined in accordance with the *Positive Discipline Policy (601).*

**Employee Reporting**

1. OSF Mission Partners (MPs) report good faith concerns of potential violations of law or regulations pertaining to the billing of research related charges by OSF business units in accordance with the following OSF Policies:
a. Integrity Line Policy (CC-107)

b. False Claims Prevention and Whistleblower Protections (CC-109)

c. Whistleblower Protection (HR-130)

d. False Claims Prevention: Federal and State False Claims and Whistleblower Laws (HR-142)

REFERENCES:


This policy is in effect for OSF Healthcare System, OSF Healthcare Foundation and all OSF Healthcare System subsidiaries and affiliates, except as limited in the header or body of this policy. For purposes of this policy, the terms “subsidiaries” and “affiliates” mean facilities or entities wholly owned or wholly controlled by OSF Healthcare System. The hospitals covered by this policy are:

<table>
<thead>
<tr>
<th>Name as listed with Medicare:</th>
</tr>
</thead>
<tbody>
<tr>
<td>X OSF St. Mary Medical Center</td>
</tr>
<tr>
<td>X OSF Saint Francis Medical Center</td>
</tr>
<tr>
<td>X OSF Saint James – John W. Albrecht Medical Center</td>
</tr>
<tr>
<td>X OSF St. Joseph Medical Center</td>
</tr>
<tr>
<td>X OSF Saint Anthony’s Health Center</td>
</tr>
</tbody>
</table>
### Approval Signatures

<table>
<thead>
<tr>
<th>Step Description</th>
<th>Approver</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Education/Communication Step (Human Protection Administrator (HPA) Listed on FWA)</td>
<td>Stephanie Madrigal: DIR CLINICAL RSRCH ADM &amp; OPR</td>
<td>2/20/2018</td>
</tr>
<tr>
<td>Board of Directors</td>
<td>Danielle McNear: EXECUTIVE ASSISTANT</td>
<td>2/19/2018</td>
</tr>
<tr>
<td>President, OSF Healthcare System</td>
<td>Sister Diane Marie: PRESIDENT</td>
<td>1/30/2018</td>
</tr>
<tr>
<td>Ministry Chief Medical Officer</td>
<td>Ralph Velazquez: SYSTEM CHIEF MEDICAL OFFICER</td>
<td>1/29/2018</td>
</tr>
<tr>
<td></td>
<td>Stephanie Madrigal: DIR CLINICAL RSRCH ADM &amp; OPR</td>
<td>1/18/2018</td>
</tr>
<tr>
<td>Human Protection Administrator (HPA) Listed on FWA</td>
<td>Stephanie Madrigal: DIR CLINICAL RSRCH ADM &amp; OPR</td>
<td>1/18/2018</td>
</tr>
<tr>
<td>Executive Director, Research Administration</td>
<td>Stephanie Madrigal: DIR CLINICAL RSRCH ADM &amp; OPR</td>
<td>1/18/2018</td>
</tr>
<tr>
<td>Research Compliance Officer</td>
<td>Heather Hermann: RESEARCH COMPLIANCE OFFICER</td>
<td>1/18/2018</td>
</tr>
<tr>
<td>Policy Review Group</td>
<td>Christen Bergstresser: RESOURCE DOCUMENT SPECIALIST</td>
<td>1/18/2018</td>
</tr>
<tr>
<td>Notification Step</td>
<td>Stephanie Madrigal: DIR CLINICAL RSRCH ADM &amp; OPR</td>
<td>12/11/2017</td>
</tr>
</tbody>
</table>